×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:RGEN

Repligen Stock Forecast, Price & News

$166.52
+4.12 (+2.54%)
(As of 07/1/2022 05:44 PM ET)
Add
Compare
Today's Range
$161.92
$166.81
50-Day Range
$140.68
$172.36
52-Week Range
$137.21
$327.32
Volume
181,586 shs
Average Volume
499,065 shs
Market Capitalization
$9.06 billion
P/E Ratio
65.82
Dividend Yield
N/A
Price Target
$301.50

Repligen Stock Forecast (MarketRank)

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.1% Upside
$301.50 Price Target
Short Interest
Bearish
6.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.58
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$2.21 M Sold Last Quarter
Proj. Earnings Growth
15.16%
From $3.10 to $3.57 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.42 out of 5 stars

Medical Sector

120th out of 1,428 stocks

Biological Products, Except Diagnostic Industry

15th out of 217 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

Repligen logo

About Repligen (NASDAQ:RGEN)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN Stock News Headlines

The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Revisiting Repligen - Seeking Alpha
Recap: Repligen Q1 Earnings - Benzinga
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
1,852
Year Founded
1981

Company Calendar

Last Earnings
4/27/2022
Today
7/02/2022
Next Earnings (Estimated)
7/26/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$301.50
High Stock Price Forecast
$335.00
Low Stock Price Forecast
$250.00
Forecasted Upside/Downside
+81.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$128.29 million
Pretax Margin
24.43%

Debt

Sales & Book Value

Annual Sales
$670.53 million
Cash Flow
$4.09 per share
Book Value
$31.65 per share

Miscellaneous

Free Float
53,830,000
Market Cap
$9.06 billion
Optionable
Optionable
Beta
0.98

Social Links















Repligen Frequently Asked Questions

Should I buy or sell Repligen stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Repligen stock.
View analyst ratings for Repligen
or view top-rated stocks.

What is Repligen's stock price forecast for 2022?

6 Wall Street analysts have issued 1-year price targets for Repligen's stock. Their RGEN stock forecasts range from $250.00 to $335.00. On average, they predict Repligen's stock price to reach $301.50 in the next twelve months. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for Repligen
or view top-rated stocks among Wall Street analysts.

How has Repligen's stock performed in 2022?

Repligen's stock was trading at $264.84 at the beginning of the year. Since then, RGEN shares have decreased by 37.1% and is now trading at $166.52.
View the best growth stocks for 2022 here
.

When is Repligen's next earnings date?

Repligen is scheduled to release its next quarterly earnings announcement on Tuesday, July 26th 2022.
View our earnings forecast for Repligen
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings results on Wednesday, April, 27th. The biotechnology company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.20. The biotechnology company earned $206.40 million during the quarter, compared to analyst estimates of $185.48 million. Repligen had a net margin of 19.86% and a trailing twelve-month return on equity of 11.13%. The company's quarterly revenue was up 44.5% on a year-over-year basis. During the same period last year, the company posted $0.68 EPS.
View Repligen's earnings history
.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share guidance of $3.07-3.15 for the period, compared to the consensus EPS estimate of $3.25. The company issued revenue guidance of $770-800 million, compared to the consensus revenue estimate of $820.31 million.

Who are Repligen's key executives?

Repligen's management team includes the following people:

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among Repligen's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Square (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $166.52.

How much money does Repligen make?

Repligen (NASDAQ:RGEN) has a market capitalization of $9.06 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.529990 on an earnings per share basis.

How many employees does Repligen have?

Repligen employs 1,852 workers across the globe.

Does Repligen have any subsidiaries?

The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More

When was Repligen founded?

Repligen was founded in 1981.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for Repligen is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.

This page (NASDAQ:RGEN) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.